Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-498-5840
Dr. Blayney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1977 - 1980
University of California San Diego School of MedicineClass of 1977
Certifications & Licensure
MI State Medical License 2003 - 2028
CA State Medical License 1978 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FASCO) American Society of Clinical Oncologists, 2007
Clinical Trials
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Start of enrollment: 2018 May 29
- Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia Start of enrollment: 2019 Oct 23
Publications & Presentations
PubMed
- Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of.Jeffrey Peppercorn, Douglas W Blayney, Linda Bosserman, John Cox
JCO Oncology Practice. 2025-05-01 - 4 citationsAutomated patient selection and care coaches to increase advance care planning for patients with cancer.Michael F Gensheimer, Winifred Teuteberg, Manali I Patel, Divya Gupta, Mahjabin Noroozi
Journal of the National Cancer Institute. 2025-02-01 - 4 citationsLong-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial.Manali I Patel, Madhuri Agrawal, Douglas W Blayney, M Kate Bundorf, Arnold Milstein
JAMA Oncology. 2024-07-01
Journal Articles
- Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non–Small Cell Lung CancerDouglas W Blayney, Santosh Nair, JAMA Oncology
Lectures
- Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and...ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphami...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
How Do Cancer Biosimilars Stack up Against the Original Products?February 4th, 2022- ‘American Ninja Warrior’ Contestant Overcame Cancer but Still Suffers from Memory Loss; Exercise Can Reduce Chemo BrainSeptember 28th, 2021
- BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual MeetingJune 7th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
